Ovensa Inc.

Ovensa Inc. is a Canadian preclinical-stage biotechnology company specializing in advanced drug delivery and nanotherapeutics, particularly in oncology and central nervous system (CNS) diseases.

The company focuses on developing innovative solutions to address challenges in drug delivery, including applications in immuno-oncology, neurodegenerative diseases, and antibiotic resistance. At the heart of Ovensa's offerings is TRIOZANTM, a proprietary nanomedicine delivery system based on trimethyl chitosan. This platform enhances the stability, bioavailability, and targeted delivery of small molecules and biologics, effectively navigating complex biological barriers like the mucosal and blood-brain barriers. Ovensa collaborates with pharmaceutical companies to improve the delivery of RNA therapeutics, antibodies, and peptides, and is advancing its lead siRNA candidate, TRIOZANTM/siRNA Gal-1, for use in head and neck cancer and recurrent glioblastoma. The company also explores additional TRIOZAN-based programs, including ligand-targeting and monoclonal antibody development, and aims to expand its applications across various industries, including pharmaceuticals, biomedicine, cosmetics, and health supplements.